Testing the amyloid hypothesis of Alzheimer's disease in vivo.
作者信息
Gandy Sam
出版信息
Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26.
Abstract
摘要
相似文献
1
Testing the amyloid hypothesis of Alzheimer's disease in vivo.在体内测试阿尔茨海默病的淀粉样蛋白假说。
Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26.
2
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.11C-PiB PET 评估 bapineuzumab 治疗阿尔茨海默病患者纤维状淀粉样β负荷的变化：一项 2 期、双盲、安慰剂对照、递增剂量研究。
Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
3
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.巴宾纽单抗治疗轻至中度阿尔茨海默病试验中的生物标志物暴露-反应分析
J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.
4
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.在使用 bapineuzumab 的 3 期随机临床试验中，ARIA-E 参与者的生物标志物模式。
Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.
5
LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo.低密度脂蛋白受体相关蛋白-1（LRP-1）基因多态性与人类体内阿尔茨海默病的整体和局部淀粉样蛋白负荷相关。
Neuroimage Clin. 2014 Feb 5;4:411-6. doi: 10.1016/j.nicl.2014.01.016. eCollection 2014.
6
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).淀粉样蛋白正电子发射断层扫描和脑脊液结果来自 crenezumab 抗淀粉样蛋白-β 抗体在轻度至中度阿尔茨海默病（BLAZE）的双盲、安慰剂对照、随机 2 期研究。
Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.
7
Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.习惯性运动水平与无症状常染色体显性阿尔茨海默病患者的脑淀粉样蛋白负荷有关。
Alzheimers Dement. 2017 Nov;13(11):1197-1206. doi: 10.1016/j.jalz.2017.03.008. Epub 2017 May 11.
8
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.匹兹堡化合物 B 正电子发射断层扫描首位阿尔茨海默病患者的正电子发射断层扫描影像与分子病理学及临床进展的关系。
Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.
9
Clinical Aspects of Alzheimer's Disease.阿尔茨海默病的临床方面
Adv Neurobiol. 2017;15:31-53. doi: 10.1007/978-3-319-57193-5_2.
10
Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease.与记忆表现相关的动态脑连接性表明了阿尔茨海默病的病理负担和遗传风险。
Alzheimers Res Ther. 2017 Mar 31;9(1):24. doi: 10.1186/s13195-017-0249-7.
引用本文的文献
1
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.针对阿尔茨海默病的治疗和预防：合理的策略和最新进展。
Annu Rev Med. 2013;64:367-83. doi: 10.1146/annurev-med-092611-084441.
2
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.人抗 Aβ IgGs 靶向合成二聚体组装体和 AD 脑源肽上的构象表位。
PLoS One. 2012;7(11):e50317. doi: 10.1371/journal.pone.0050317. Epub 2012 Nov 27.
3
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.抗体对可溶性、突触毒性淀粉样β 物种的中和作用具有表位特异性。
J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.
4
Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.经颅近红外激光治疗在急性和慢性神经退行性疾病中的应用促进临床恢复。
Expert Rev Med Devices. 2012 Jan;9(1):71-83. doi: 10.1586/erd.11.64.
5
A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.一种针对合成 Aβ 二聚体组装物的单克隆抗体可中和脑源性破坏突触可塑性的 Aβ。
J Neurochem. 2011 Oct;119(1):189-201. doi: 10.1111/j.1471-4159.2011.07389.x. Epub 2011 Aug 22.
6
New pathway links γ-secretase to inflammation and memory while sparing notch.新途径将γ-分泌酶与炎症和记忆联系起来，同时不影响Notch信号通路。
Ann Neurol. 2011 Jan;69(1):5-7. doi: 10.1002/ana.22310.
本文引用的文献
1
Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.
Dokl Biochem Biophys. 2009 Sep-Oct;428:235-8. doi: 10.1134/s1607672909050032.
2
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.11C-PiB PET 评估 bapineuzumab 治疗阿尔茨海默病患者纤维状淀粉样β负荷的变化：一项 2 期、双盲、安慰剂对照、递增剂量研究。
Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
3
Can Alzheimer disease be prevented by amyloid-beta immunotherapy?阿尔茨海默病能否通过淀粉样蛋白-β免疫疗法预防？
Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219.
4
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.β-淀粉样寡聚体：在阿尔茨海默病中作为关键神经毒素的可能作用。
Mt Sinai J Med. 2010 Jan-Feb;77(1):43-9. doi: 10.1002/msj.20160.
5
Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.拉曲匹定，一种治疗阿尔茨海默病和亨廷顿舞蹈症的潜在新型药物。
Curr Opin Investig Drugs. 2010 Jan;11(1):80-91.
6
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.急性给予拉替吡啶（Dimebon），一种可能的阿尔茨海默病治疗药物，可提高体外和体内细胞外淀粉样β水平。
Mol Neurodegener. 2009 Dec 17;4:51. doi: 10.1186/1750-1326-4-51.
7
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.他克林对轻中度阿尔茨海默病患者认知功能下降及日常生活活动能力的影响：一项随机对照试验。
JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.
8
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.一项在轻度至中度阿尔茨海默病中进行的 bapineuzumab 多剂量递增的 2 期临床试验。
Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.
9
Homotaurine: a failed drug for Alzheimer's disease and now a nutraceutical for memory protection.
Am J Health Syst Pharm. 2009 Nov 1;66(21):1950-3. doi: 10.2146/ajhp080576.
10
Abeta species removal after abeta42 immunization.β淀粉样蛋白42免疫后β淀粉样蛋白的清除
J Neuropathol Exp Neurol. 2006 Nov;65(11):1040-8. doi: 10.1097/01.jnen.0000240466.10758.ce.
Zotero 插件